Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company focused on pioneering novel cancer therapies. The company specializes in the discovery, development, and commercialization of drugs targeting nuclear export proteins for the treatment of cancer and other significant diseases. Its flagship product, XPOVIO® (selinexor), is a first-in-class, oral exportin 1 (XPO1) inhibitor and is approved in the U.S. for multiple oncology indications. These include combination therapies with Velcade® (bortezomib) and dexamethasone for multiple myeloma, as well as treatments for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Recent achievements highlight the company's commitment to advancing its late-stage clinical pipeline. Notably, Karyopharm has been at the forefront in evaluating selinexor's efficacy in combination therapies for multiple myeloma, endometrial cancer, and myelofibrosis. The company recently reported long-term follow-up data from a Phase 1/3 study on selinexor in combination with ruxolitinib in myelofibrosis patients, showing promising results in spleen volume and symptom reduction.
Financially, Karyopharm reported total revenue of $33.7 million for Q4 2023, with a full-year revenue of $146.0 million. Despite a competitive market, the company managed to maintain steady growth and focused resources on its high-potential pipeline. With a cash position of $192.4 million as of December 31, 2023, Karyopharm is well-positioned to continue its innovative research and development efforts.
Karyopharm's collaborations with global partners, including Antengene, Menarini, Neopharm, and FORUS, have extended the reach of XPOVIO to various international markets such as Europe, China, South Korea, and Israel. This international expansion underscores the global demand for innovative cancer therapies.
For more information, please visit www.karyopharm.com.
Karyopharm Therapeutics (KPTI) has announced a 1-for-15 reverse stock split effective February 25, 2025, at 5:00 p.m. Eastern Time. The split aims to increase the per-share market price to regain compliance with Nasdaq's minimum bid price requirement.
The stock will begin trading on a split-adjusted basis on February 26, 2025. The reverse split will reduce outstanding shares from approximately 126.2 million to 8.4 million, and authorized shares from 800 million to 53.3 million. Proportionate adjustments will be made to equity incentive plans, outstanding equity awards, warrants, and convertible notes.
No fractional shares will be issued; stockholders will receive cash payments instead. Computershare Trust Company is acting as the exchange agent, and stockholders holding shares electronically need not take action to receive post-split shares.
Karyopharm Therapeutics reported financial results for Q4 and full year 2024, achieving total revenue of $145.2 million and U.S. XPOVIO net product revenue of $112.8 million for the full year. The company provided 2025 guidance with total revenue expected between $140-155 million.
Key updates include modifications to the Phase 3 XPORT-EC-042 trial in endometrial cancer, with enrollment now focusing on patients with pMMR tumors or dMMR tumors ineligible for checkpoint inhibitors. The sample size has been increased to 276 patients, with top-line data expected in mid-2026.
The Phase 3 SENTRY trial in myelofibrosis is on track for enrollment completion in 1H 2025, with top-line data expected in 2H 2025. The company's cash position was $109.1 million as of December 31, 2024, expected to fund operations into Q1 2026.
Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has scheduled its fourth quarter and full year 2024 financial results announcement for Wednesday, February 19, 2025. The company will host a conference call and audio webcast at 8:00 a.m. ET on the same day.
Investors can access the conference call via phone at (800) 836-8184 (local) or (646) 357-8785 (international). The webcast and accompanying slides will be available in the Investor section of Karyopharm's website under 'Events & Presentations', with an archived version accessible approximately two hours after the event.
Karyopharm Therapeutics (Nasdaq: KPTI) has announced the granting of 28,000 restricted stock units (RSUs) to three newly-hired employees as of January 31, 2025. These RSU awards were granted under the Company's 2022 Inducement Stock Incentive Plan, in compliance with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest over three years, with 33 1/3% vesting on each anniversary of the grant date, contingent upon continued employment. In case of a change in control event, the RSUs will fully vest if the employee's employment is terminated for good reason or without cause within one year of such event.
Karyopharm Therapeutics (KPTI) announced preliminary unaudited 2024 results and 2025 objectives. The company expects total revenue of approximately $145 million and U.S. XPOVIO net product revenue of $113 million for full year 2024.
Key highlights include the Phase 3 SENTRY trial evaluating selinexor in myelofibrosis, with top-line results expected in H2 2025. The company updated the trial's co-primary endpoint to absolute mean change in total symptom score (Abs-TSS) and increased the sample size to 350 patients.
XPOVIO showed consistent demand in 2024 versus 2023, with growth in H2 2024 in both community and academic settings. The drug is now approved in over 45 countries. Cash position stands at approximately $109 million as of December 31, 2024, expected to fund operations into Q1 2026.
Karyopharm Therapeutics (NASDAQ: KPTI) has announced equity grants to four newly-hired employees as of December 31, 2024. The grants include 101,250 stock options with an exercise price of $0.6763 per share and 108,540 restricted stock units (RSUs).
The stock options vest over four years, with 25% vesting after one year and 1/48th monthly thereafter. The RSUs vest over three years, with 33 1/3% vesting annually. Both grants require continued employment with Karyopharm. In case of a change in control event followed by termination for good reason or without cause within one year, all grants will immediately vest in full.
Karyopharm Therapeutics (Nasdaq: KPTI) has appointed Lori Macomber as Executive Vice President, Chief Financial Officer and Treasurer, effective January 3, 2025. Macomber brings over 20 years of experience in life science companies' financial management, most recently serving as CFO at Legend Biotech
As part of her appointment, Macomber will receive inducement awards including a non-statutory stock option to purchase 650,000 shares and 160,000 restricted stock units (RSUs). The stock options will vest over four years, with 25% vesting after the first year and 1/48th monthly thereafter. The RSUs will vest over three years, with 33 1/3% vesting annually. Both awards include immediate vesting provisions in case of a change in control event followed by qualifying termination.
Karyopharm Therapeutics (Nasdaq: KPTI) has appointed Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications. Strong joins from Argot Partners, where he served as Managing Director advising biopharmaceutical companies. His previous experience includes roles as investor relations lead at Tenet Healthcare, CFO of Tenet's Massachusetts Market, and equity research positions at Lehman Brothers and Barclays.
The company emphasizes Strong's experience will be valuable as they approach important milestones in 2025, particularly in advancing their late-stage pipeline and building on their multiple myeloma foundation. Strong holds an MBA from Harvard Business School and a B.S. in Finance from Rutgers University.
Karyopharm Therapeutics (Nasdaq: KPTI) announced it is in discussions with the FDA regarding the evolving treatment landscape in endometrial cancer and potential implications for their Phase 3 XPORT-EC-042 trial. Due to these ongoing discussions, the company will not address its endometrial cancer program at the Piper Sandler Healthcare Conference. An update will be provided after the FDA discussion concludes.
Karyopharm Therapeutics has announced the granting of 4,800 restricted stock units (RSUs) to two newly-hired employees as of November 30, 2024. The RSUs were granted under the company's 2022 Inducement Stock Incentive Plan, following Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over three years, with 33 1/3% vesting annually. Full vesting is subject to continued employment, with immediate vesting possible in case of qualifying termination following a change in control event.
FAQ
What is the current stock price of Karyopharm Therapeutics (KPTI)?
What is the market cap of Karyopharm Therapeutics (KPTI)?
What is Karyopharm Therapeutics' main focus?
What is XPOVIO® (selinexor)?
What recent achievements has Karyopharm reported?
Who are Karyopharm's global partners?
What are Karyopharm's financial highlights?
What are the key indications for XPOVIO?
What is the significance of Karyopharm's research on nuclear export proteins?
How does Karyopharm support clinical trials and research?
What are the safety considerations for XPOVIO?
How can I get more information about Karyopharm's products or clinical trials?
